BIOMAT Database Logo BIOMAT Database Logo

CSF neurofilament and glial fibrillary acidic protein in normal pressure hydrocephalus. 1998

M Tullberg, and L Rosengren, and E Blomsterwall, and J E Karlsson, and C Wikkelsö
Institution of Clinical Neuroscience, University of Göteborg, Sweden.

We examined CSF levels of markers of neuronal degeneration and astrogliosis-the light subunit of the neurofilament triplet protein (NFL) and the glial fibrillary acidic protein (GFAP)-in 65 patients with normal pressure hydrocephalus (NPH). NFL was increased sixfold (864 +/- 1,538 [mean +/- SD] versus 156 +/- 81 ng/L; p < or = 0.001) and GFAP twofold (1,116 +/- 1,085 versus 637 +/- 295 ng/L; p < or = 0.01) in NPH patients compared with neurologically healthy age-matched controls. No correlation was found between any particular symptom or sign and GFAP levels in CSF. The levels of NFL, on the other hand, were higher in patients with severe symptoms compared with those with moderate or no symptoms. Furthermore, there was a correlation between a high level of NFL and gait disturbance, incontinence, psychometric incapability, and social dysfunction. A high preoperative NFL level was associated with favorable outcome after shunt surgery. This indicates that NFL is a marker of ongoing and possibly still-reversible axonal damage in NPH.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009410 Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways. Neuron Degeneration,Degeneration, Nerve,Degeneration, Neuron,Degenerations, Nerve,Degenerations, Neuron,Nerve Degenerations,Neuron Degenerations
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D002557 Cerebrospinal Fluid Shunts Tubes inserted to create communication between a cerebral ventricle and the internal jugular vein. Their emplacement permits draining of cerebrospinal fluid for relief of hydrocephalus or other condition leading to fluid accumulation in the ventricles. Cerebrospinal Fluid Shunt,Shunt, Cerebrospinal Fluid,Shunts, Cerebrospinal Fluid
D005260 Female Females
D005684 Gait Manner or style of walking. Gaits
D005904 Glial Fibrillary Acidic Protein An intermediate filament protein found only in glial cells or cells of glial origin. MW 51,000. Glial Intermediate Filament Protein,Astroprotein,GFA-Protein,Glial Fibrillary Acid Protein,GFA Protein
D005911 Gliosis The production of a dense fibrous network of neuroglia; includes astrocytosis, which is a proliferation of astrocytes in the area of a degenerative lesion. Astrocytosis,Astrogliosis,Glial Scar,Astrocytoses,Glial Scars,Scar, Glial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Tullberg, and L Rosengren, and E Blomsterwall, and J E Karlsson, and C Wikkelsö
[Glial fibrillary acidic protein and neurofilament protein in medulloblastoma].
October 1988, No shinkei geka. Neurological surgery,
M Tullberg, and L Rosengren, and E Blomsterwall, and J E Karlsson, and C Wikkelsö
Neurofilament and glial fibrillary acidic protein in multiple sclerosis.
November 2004, Neurology,
M Tullberg, and L Rosengren, and E Blomsterwall, and J E Karlsson, and C Wikkelsö
High cerebrospinal fluid concentration of glial fibrillary acidic protein (GFAP) in patients with normal pressure hydrocephalus.
October 1985, Journal of the neurological sciences,
M Tullberg, and L Rosengren, and E Blomsterwall, and J E Karlsson, and C Wikkelsö
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS.
August 2004, Neurology,
M Tullberg, and L Rosengren, and E Blomsterwall, and J E Karlsson, and C Wikkelsö
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS.
December 2003, Neurology,
M Tullberg, and L Rosengren, and E Blomsterwall, and J E Karlsson, and C Wikkelsö
Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy.
March 2022, Brain : a journal of neurology,
M Tullberg, and L Rosengren, and E Blomsterwall, and J E Karlsson, and C Wikkelsö
Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis.
November 2023, Multiple sclerosis and related disorders,
M Tullberg, and L Rosengren, and E Blomsterwall, and J E Karlsson, and C Wikkelsö
Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL.
April 2020, Journal of neuroinflammation,
M Tullberg, and L Rosengren, and E Blomsterwall, and J E Karlsson, and C Wikkelsö
Cerebrospinal fluid neurofilament and glial fibrillary acidic protein in patients with cerebral vasculitis.
March 2002, Journal of neuroscience research,
M Tullberg, and L Rosengren, and E Blomsterwall, and J E Karlsson, and C Wikkelsö
Glial fibrillary acidic protein and neurofilament in children with cerebral white matter abnormalities.
December 2001, Neuropediatrics,
Copied contents to your clipboard!